Filing Details

Accession Number:
0001819790-21-000059
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-03 18:56:58
Reporting Period:
2021-12-01
Accepted Time:
2021-12-03 18:56:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1819790 Tarsus Pharmaceuticals Inc. TARS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1791249 Michael Ackermann C/O Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine CA 92618
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-12-01 2,442 $23.85 1,207,407 No 4 S Direct
Common Stock Disposition 2021-12-01 2,054 $24.68 1,205,353 No 4 S Direct
Common Stock Disposition 2021-12-01 809 $25.87 1,204,544 No 4 S Direct
Common Stock Disposition 2021-12-01 528 $26.65 1,204,016 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $23.24 to $24.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $24.28 to $25.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.51 to $26.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.53 to $27.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.